Chime Biologics Hosts OASES Delegation at Europe Innovation Hub in Basel, Switzerland

September 16 2025 , Basel, Switzerland – Chime Biologics, a leading global CDMO that enables its partners' success in biologics, was honored to welcome Mr. Peter Yan, Director-General, Mr. Bryan Peng, Executive Director, and Maggie LO, Chief Manager (Life and Health Technology) of the Office for Attracting Strategic Enterprises (OASES) to its Europe Innovation Hub in Basel, Switzerland.

The visit underscored the strategic importance of Chime Biologics’ expansion in Europe and the role of its Europe Innovation Hub in bridging biopharmaceutical enterprises across continents. As a global life sciences cluster, Basel provides a vibrant ecosystem for innovation, talent, and partnerships, offering valuable insights to OASES on cross-continent enterprise development in the biopharmaceutical industry.

During the visit, Chime Biologics shared its experience in agile integration into the biopharma campus in Basel to provide services to biopharma companies in Europe locally with the support of global expertise and facilities, highlighting practical knowledge of global-standard innovation incubation. These learnings are highly relevant to OASES as it strengthens its engagement with global biopharma enterprises and positions Hong Kong as a hub for international innovation and technology.

Chime Biologics also expressed its commitment to supporting OASES as a gateway to connect global biopharma companies with opportunities in Hong Kong. By strategically establishing their presence in Hong Kong, companies can leverage its advantages as an international innovation hub and expand into the rapidly growing China market.

About Chime Biologics

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologic medicines to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 500 skilled employees, we share a common goal to make cutting-edge biomedicines affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally. For more information, please visit www.chimebiologics.com.